Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.

Two Novartis leaders share their perspectives on digital health in 2020 – and the key trends to watch out for over the next 12 months.

AI is already accelerating drug discovery and health delivery. It has great potential to accelerate research, workflow and processes, and even reengineer entire healthcare systems. But what challenges must be addressed first? Shahram Ebadollahi and Ann Aerts share the ideas they discussed at the Intelligent Health summit in Basel this week.

Novartis researchers are using data to accelerate drug development.

The recently appointed leader of the Novartis’ digital research and development platform data42 is a strong believer that data and digital technologies will change the path of medical science.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Novartis CEO Vas Narasimhan answers questions about COVID-19.